| Diabetes Mellitus, Non-Insulin-Dependent
Inpefa vs Invokamet
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Inpefa vs Invokamet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInvokamet has a higher rate of injection site reactions vs Inpefa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Invokamet but not Inpefa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inpefa
Invokamet
At A Glance
Oral
Daily
SGLT1/SGLT2 inhibitor
Oral
Once or twice daily
SGLT2 inhibitor + biguanide
Indications
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetic Nephropathy
Dosing
Heart failure, Diabetes Mellitus, Non-Insulin-Dependent, Chronic Kidney Diseases 200 mg orally once daily, not more than one hour before the first meal; titrate after at least 2 weeks to 400 mg once daily as tolerated; down-titrate to 200 mg as necessary.
Diabetes Mellitus, Non-Insulin-Dependent INVOKAMET: One tablet orally twice daily with meals, starting at canagliflozin 100 mg and metformin HCl 1,000 mg total daily dose. INVOKAMET XR: Two tablets orally once daily with morning meal, swallow whole. Maximum: canagliflozin 300 mg and metformin HCl 2,000 mg total daily. Not recommended if eGFR <45 mL/min/1.73 m2. Dose adjust for renal impairment: eGFR 45-60, max canagliflozin 100 mg daily; eGFR 30-45, assess benefit/risk, max canagliflozin 100 mg daily.
Diabetic Nephropathy Canagliflozin 100 mg orally once daily as a component of INVOKAMET or INVOKAMET XR. Dose adjust based on eGFR. Contraindicated if eGFR <30 mL/min/1.73 m2.
Contraindications
- History of serious hypersensitivity reaction to INPEFA
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Serious hypersensitivity reaction to canagliflozin or metformin HCl, such as anaphylaxis or angioedema
Adverse Reactions
Most common (>=2%) Urinary tract infection, volume depletion, diarrhea, hypoglycemia, dizziness, genital mycotic infection
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin and insulin secretagogues, necrotizing fasciitis of the perineum, genital mycotic infections
Most common (>=2%) Urinary tract infections, increased urination, thirst, constipation, nausea, female genital mycotic infections, vulvovaginal pruritus, male genital mycotic infections
Serious Lactic acidosis, diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, bone fracture
Postmarketing Ketoacidosis, acute kidney injury, anaphylaxis, angioedema, urosepsis and pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), cholestatic hepatocellular and mixed hepatocellular liver injury
Pharmacology
Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1; SGLT2 inhibition reduces renal reabsorption of glucose and sodium (lowering cardiac pre- and afterload and downregulating sympathetic activity), while SGLT1 inhibition reduces intestinal absorption of glucose and sodium.
Canagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal threshold for glucose, and increases urinary glucose excretion, thereby lowering plasma glucose. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inpefa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
Invokamet
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Inpefa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Invokamet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Inpefa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Invokamet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Inpefa Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Invokamet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InpefaView full Inpefa profile
InvokametView full Invokamet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.